GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tetraphase Pharmaceuticals Inc (NAS:TTPH) » Definitions » Interest Coverage

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Interest Coverage : N/A (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Tetraphase Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tetraphase Pharmaceuticals's Operating Income for the three months ended in Mar. 2020 was $-12.26 Mil. Tetraphase Pharmaceuticals's Interest Expense for the three months ended in Mar. 2020 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Tetraphase Pharmaceuticals's Interest Coverage or its related term are showing as below:


TTPH's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 129.84
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tetraphase Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Tetraphase Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tetraphase Pharmaceuticals Interest Coverage Chart

Tetraphase Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - No Debt No Debt - -

Tetraphase Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - N/A N/A

Competitive Comparison of Tetraphase Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tetraphase Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's Interest Coverage falls into.



Tetraphase Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tetraphase Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as

Here, for the fiscal year that ended in Dec. 2019, Tetraphase Pharmaceuticals's Interest Expense was $-2.58 Mil. Its Operating Income was $-67.53 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.45 Mil.

Tetraphase Pharmaceuticals did not have earnings to cover the interest expense.

Tetraphase Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2020 is calculated as

Here, for the three months ended in Mar. 2020, Tetraphase Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-12.26 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.75 Mil.

GuruFocus does not calculate Tetraphase Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Tetraphase Pharmaceuticals  (NAS:TTPH) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Tetraphase Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.
Executives
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Larry G. Edwards director, officer: See Remarks C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Geraldine Henwood director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David Charles Lubner officer: SVP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Headlines

From GuruFocus

Insiders Roundup: Tetraphase Pharmaceuticals, Bank Of America

By Tiziano Frateschi Tiziano Frateschi 07-31-2020

Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals

By Business Wire Business Wire 06-04-2020